PSI Insights
Explore
Feature
High placebo response rates in Crohn’s disease and ulcerative colitis trials continue to challenge endpoint interpretability, power assumptions, and development timelines. Download PSI’s new white paper for a practical framework to reduce placebo susceptibility in IBD studies through patient selection, endpoint strategy, corticosteroid management, and operational controls.
Industry Commentary
Does owning a central lab improve trial execution, or limit the ability to choose the right lab for the study?
Central Laboratory Strategy, Clinical Trial Operations